{"symbol":"REGN","fiscalQuarter":"Q2-2013","reportDate":"2013-08-06","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q2-2013","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Down 6.1%","keyNumbers":[{"metric":"EPS","actual":"$1.73","expected":"N/A","surprise":"+100.46%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted ongoing research and development efforts.","They expressed confidence in their pipeline despite market challenges."],"summary":"Overall, management conveyed a sense of optimism regarding future product developments. However, they acknowledged the competitive landscape."},"guidanceChanges":{"summary":"No guidance data was provided in this earnings report.","changes":[]},"whatItMeans":"Regeneron's strong EPS performance indicates better-than-expected profitability, but the stock fell by 6.1% in reaction. Investors may be concerned about the lack of revenue details and future guidance. The cautious tone from management suggests that while they are optimistic, there are challenges ahead that could impact growth.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q2 2013 earnings: EPS beat expectations. Stock down 6.1%. Full breakdown."}}